Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in Moderately to Severely Active Ulcerative Colitis
NCT03945188Phase 3Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jun 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 40
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Etrasimod 2 mg with Placebo (2 arms). Primary endpoints: Percentage of Participants Achieving Clinical Remission at Week 12 and Percentage of Participants Achieving Clinical Remission at Week 52. Started Jun 2019; status: completed.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03945188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945188.